🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"If you have to worry about whether you have food for dinner that evening, and for the rent on Friday, you have little space to think about anything else. Such stress can permanently affect the development of your children". theguardian.com/commentisfree/…

The size of the US pharmaceutical market means that the US Food and Drug Administration has a disproportionately large global influence writes Robin Forrest of LSE Health Policy bit.ly/3GVeIme

Congratulations to our seven PhD Grant Recipients for 2022-23! Read more about our PhD grants scheme 👇 lse.ac.uk/united-states/…

In new JAMA Health Forum paper, LSE Health Policy’s Huseyin Naci and Robin Forrest examine the insurer restrictions on new drugs in the US Medicare program➡️bit.ly/3kqCJdT Aaron Kesselheim Program On Regulation, Therapeutics, And Law

Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, according this cross-sectional study. LSE Health Policy Research Portal Aaron Kesselheim Robin Forrest ja.ma/41ntf3G

Want to learn more about pharmaceutical policy and economics? In a new report commissioned by The Health Foundation #REAL Centre, the Department’s Huseyin Naci & Robin Forrest explain pharmaceutical discovery, development, approval and adoption. ➡️ Access here: bit.ly/41FbIUU

NEW: Our #REALCentre commissioned LSE Health Policy to research pharmaceutical policy in the UK. They identify 🔎 ▶️ shortcomings of current pharmaceutical policy ▶️ key principles for building a more coherent system. Read the final reports 🔽 health.org.uk/funding-and-pa…

Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, according this cross-sectional study. LSE Health Policy Research Portal Aaron Kesselheim Robin Forrest ja.ma/3lK4vCD

Every five years or so, an agreement is brokered between the UK government and the drug industry that shapes the pricing and reimbursement landscape for medicines. What do we need to know ahead of negotiations for the next version of the agreement? bmj.com/content/381/bm…

In a new The BMJ editorial, the department’s Robin Forrest and Huseyin Naci discuss how the UK Government can prioritise patients in ongoing negotiations with the pharmaceutical industry over drug pricing. Access full editorial from here: ➡️ bit.ly/3UKt4ws

Also Online First: #Overallsurvival benefits of #cancerdrugs initially approved by the US Food and Drug Administration U.S. FDA on the basis of immature survival data: a retrospective analysis thelancet.com/journals/lanon…

🚨Our article out today in The Lancet Oncology Are countries harmonizing up or down? A 🧵 We examine the clinical benefit, #HTA review times, and prices of drugs reviewed through Project Orbis Cc: Vinay Prasad MD MPH Arianna Gentilini Alyson Haslam

Online First: Preferences for speed of access versus certainty of the #survival benefit of new #cancerdrugs: a discrete choice experiment thelancet.com/journals/lanon…

A very relevant and meaningful study. Understanding patients’ preferences for speed versus certainty of benefit- the trade-off of accelerated approval.

Interesting new work from authors LSE Health Policy! 'Although people with experience of cancer place high value on faster access to new drugs, they also place utmost value on high certainty that new cancer drugs will ultimately offer survival benefit.' thelancet.com/journals/lanon…

NEW 💊 Cancer patients could be willing to wait for certainty of the benefit of cancer drugs before they're approved by the FDA. More on The Lancet Oncology #CancerResearch by Robin Forrest & Huseyin Naci LSE Health Policy & Dr. Mylene Lagarde Ajay Aggarwal. ow.ly/kn2X50Ub06Z

To what extent would individuals be willing to wait in exchange for greater certainty of the survival benefit of new cancer drugs? New study in The Lancet Oncology by Robin Forrest, Dr. Mylene Lagarde, Ajay Aggarwal, & Dr. Huseyin Naci. Read now🔗bit.ly/3CAKqXD

Interesting piece from Vinay Prasad MD MPH on surrogate endpoints and their (potential) impact on efficiency and the cancer drug pipeline. Good to see our study discussed in context!